Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment

Autor: Andrea Weiss, Connie R. Jimenez, Patrycja Nowak-Sliwinska, Pierre-Yves Dietrich, Alexander A. Henneman, Marloes Zoetemelk, Mylène Docquier, Youssef Daali, Thibaud Koessler, Magdalena Rausch, Céline Delucinge-Vivier, Thomas Alexander Mckee, Axel Andres, Christian Toso, Tatiana V. Petrova, Richard R. de Haas, Simone Ragusa, Sander R. Piersma, George Mourad Ramzy, Arjan W. Griffioen, Valentin Mieville, Laura Rubbia-Brandt, Judy R. van Beijnum

Publikováno v: Molecular Oncology
Molecular oncology, vol. 14, no. 11, pp. 2894-2919
Molecular Oncology (2020)
Zoetemelk, M, Ramzy, G M, Rausch, M, Koessler, T, van Beijnum, J R, Weiss, A, Mieville, V, Piersma, S R, de Haas, R R, Delucinge-Vivier, C L, Andres, A, Toso, C, Henneman, A A, Ragusa, S, Petrova, T V, Docquier, M, McKee, T A, Jimenez, C R, Daali, Y, Griffioen, A W, Rubbia-Brandt, L, Dietrich, P-Y & Nowak-Sliwinska, P 2020, ' Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment ', Molecular oncology, vol. 14, no. 11, pp. 2894-2919 . https://doi.org/10.1002/1878-0261.12797
Molecular oncology, 14(11), 2894-2919. Elsevier
Molecular Oncology, Vol 14, Iss 11, Pp 2894-2919 (2020)

Therapeutically guided multidrug optimization (TGMO) technology, composed of experimental testing and in silico modelling, allowed identification of synergistic and selective low‐dose optimized drug combinations (ODCs) active in multiple colorectal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697c0adf39c6243b6ff93e1d09b7bbfb
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85092087787&origin=inward

Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering

Autor: Andrea Weiss, Katayoun Falamaki, Patrick Meraldi, Marijana Miljkovic-Licina, Marloes Zoetemelk, Bernard Wehrle-Haller, Daniela Harry, Magdalena Rausch, Patrycja Nowak-Sliwinska, George Mourad Ramzy, Morgan Le Roux-Bourdieu

Publikováno v: Cancers
Volume 11
Issue 10
Cancers, Vol. 11, No 10 (2019) P. 1612
Cancers, Vol 11, Iss 10, p 1612 (2019)

A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity. To address this, we performed a phenotypically-driven screen to identify optimal multidrug combinations acting with high efficacy and selectivity in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666893051a25ac9692020e9eba9195a2